文献速递药物不良反应与药物警戒特殊人群用药

社区药房推广芬戈莫德患者照护过渡、安全与用药依从性服务

Promoting transitions of care, safety, and medication adherence for patients taking fingolimod in community pharmacies.
PubMed 文献 · Am J Health Syst Pharm · 2019-01-01

本文描述了一种在社区药房网络中开发并推广的芬戈莫德专科药学服务(F-PSP),旨在通过用药依从性支持和药物警戒两项干预,促进患者安全与赋能。该服务结合动机性访谈与电子监测,并由过渡期照护药师协调入组与转介,同时产生真实世界数据。

要点

  • F-PSP通过动机性访谈与纵向电子用药监测支持芬戈莫德用药依从性。
  • 药物警戒部分包括告知推荐、提醒医学检查及追踪潜在严重不良反应症状。
  • 过渡期照护药师负责向所有新起始芬戈莫德患者推荐入组并协调转介至社区药房。

核心结论

  • F-PSP能够支持个体患者并提供真实世界数据,有助于弥合实践与研究之间的差距。
  • F-PSP旨在成为一种可转移至其他医疗背景、专科药物或疾病的通用专科药学服务模型。

研究设计与样本

  • 本文描述了F-PSP在社区药房网络内的开发与推广,未报告研究设计或样本量。

主要发现

  • F-PSP通过用药依从性支持和药物警戒两项干预补充基础药学服务。
  • 依从性干预将动机性访谈与纵向电子用药依从性监测相结合。
  • 药物警戒部分包括告知患者芬戈莫德推荐、提醒推荐医学检查及追踪监测症状,尤其是潜在严重不良反应症状。
  • 安全网络平台指导药师进行访谈并收集患者报告结局数据。
  • 过渡期照护药师向所有新起始芬戈莫德患者提议参与、执行入组并协调转至患者指定社区药房进行持续照护。

临床怎么用

  • 社区药师可通过F-PSP对芬戈莫德患者实施结构化依从性支持与药物警戒监测。
  • 过渡期照护药师可在患者起始芬戈莫德时推荐入组并协调社区药房转介。
  • 药师可利用安全网络平台指导访谈并收集患者报告结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The development and dissemination of a specialty pharmacy service to optimize fingolimod therapy management are described. SUMMARY: Fingolimod was the first oral therapy developed to counter relapsing-remitting multiple sclerosis. Pharmacovigilance measures and individualized support are strongly recommended due to associated safety concerns. The Fingolimod Patient Support Program (F-PSP) was developed and disseminated within a community pharmacy network. The F-PSP aims to ensure responsible use of fingolimod and patient empowerment by promoting medication adherence and patient safety through a person-centered and integrated care approach. It complements basic pharmacy services through 2 interventions: medication adherence support and pharmacovigilance tailored to fingolimod. The adherence intervention combines motivational interviewing with longitudinal electronic medication adherence monitoring. The pharmacovigilance component consists of informing patients of fingolimod recommendations, reminding patients of recommended medical tests, and tracking and monitoring symptoms, especially those of potential serious adverse fingolimod reactions. A secure Web platform guides the pharmacist in conducting interviews and enables collection of patient-reported outcome data. A transition care pharmacist proposes program participation to all patients initiated on fingolimod, performs enrollment, and coordinates transfers to patient-designated community pharmacies for ongoing care. CONCLUSION: The F-PSP enables support of individual patients, and also provides real-world data, helping to bridge the gap between practice and research. The F-PSP is intended to be a generic model of a specialty pharmacy service that is transferable to any other healthcare context, specialty drug or disease.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Bourdin A, Schluep M, Bugnon O, et al. Promoting transitions of care, safety, and medication adherence for patients taking fingolimod in community pharmacies. Am J Health Syst Pharm. 2019. PMID: 31201774. doi:10.1093/ajhp/zxz106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。